Reappraisal of the safety and efficacy of cefuroxime dispersible tablet in the world market

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-17010365

Enrollment

Unknown

Registered

2017-01-09

Start date

2017-01-06

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensitive infections caused by bacteria

Interventions

Case series:Cefuroxime axetil dispersible tablets

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Prescription of cefuroxime axetil dispersible tablets in patients.

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

Measure	Time frame
Bacterial clearance rate;	—

Countries

China

Contacts

Public ContactXiaojun Ma

Peking Union Medical College Hospital

drmaxiaojun@sina.com+86 13911378823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026